<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145310</url>
  </required_header>
  <id_info>
    <org_study_id>BOL-P-11</org_study_id>
    <nct_id>NCT04145310</nct_id>
  </id_info>
  <brief_title>BOL-DP-o-04 in Patients With Low Back Pain and Sciatica</brief_title>
  <official_title>A Prospective, Single-Center, Double-Blind, Placebo-Controlled Trial of BOL-DP-o-04 in Patients With Low Back Pain and Sciatica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breath of Life International Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Breath of Life International Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to evaluate the pain-relieving effect of BOL-DP-o-04, in addition to SOC,&#xD;
      on Low Back Pain and Sciatica.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Prospective, Single-Center, Double-Blind, Placebo-Controlled Trial of BOL-DP-o-04 in&#xD;
      Patients with Low Back Pain and Sciatica. The study is aimed to evaluate the pain-relieving&#xD;
      effect of BOL-DP-o-04, in addition to SOC, on Low Back Pain and Sciatica.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>Baseline to Day 114</time_frame>
    <description>Change in the Oswestry Disability Index. The questionnaire is composed by 10 sections Each section can be scored 0 to 5, 5 being the worst case. The score is calculated by summing the different sections and then doubling the total. Maximum score is 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Index</measure>
    <time_frame>Baseline to Day 100</time_frame>
    <description>Change in the Brief Pain Index relative to baseline. The Brief Pain Inventory rapidly assesses the severity of pain and its impact on functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (SF12) Mental</measure>
    <time_frame>Screening to Day 100</time_frame>
    <description>Change in Short Form (SF12) Mental Composite Score.The SF-12 consists of a subset of 12 items that measure eight health domains to assess physical and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>Screening to Day 100</time_frame>
    <description>Change in Pittsburgh Sleep Quality Index. The Pittsburgh Sleep Quality Index is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opiate consumption and analgesic medication consumption</measure>
    <time_frame>Screening to Day 100</time_frame>
    <description>Change in Opiate consumption and analgesic medication consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression</measure>
    <time_frame>Baseline to Day 100</time_frame>
    <description>Change in Patient global impression. The Patient Global Impression is a 7 point scale depicting a patient's rating of overall improvement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Low Back Pain</condition>
  <condition>Sciatica</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-DP-o-04 + SCO</intervention_name>
    <description>sublingual drops</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + SCO</intervention_name>
    <description>sublingual drops</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt;18 years of age&#xD;
&#xD;
          2. Mild to Severe Low Back Pain and/or Sciatica&#xD;
&#xD;
          3. Imaging studies (CT or MRI) supporting anatomical abnormality that could be the cause&#xD;
             of the symptoms&#xD;
&#xD;
          4. Must be physically and mentally willing and able to comply with the treatment regimen&#xD;
             and understand the informed consent and study procedures&#xD;
&#xD;
          5. Signed and dated Informed Consent Form (ICF)&#xD;
&#xD;
          6. Non-responsive to standard therapy for at least 1 month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. VAS Pain Subscale score at Screening is less than 6 (with 0 being no pain and 10 being&#xD;
             worse imaginable pain)&#xD;
&#xD;
          2. Known allergy to cannabis or its components&#xD;
&#xD;
          3. A patient who is pregnant or intends to become pregnant during the study&#xD;
&#xD;
          4. A patient who is nursing or intends to nurse during the study&#xD;
&#xD;
          5. A patient suffering from a mental disorder precluding administration of study drug&#xD;
&#xD;
          6. Prisoners&#xD;
&#xD;
          7. A Patient is unable to sign an informed consent form&#xD;
&#xD;
          8. Unstable angina pectoris&#xD;
&#xD;
          9. Cardiac insufficiency precluding cannabis administration&#xD;
&#xD;
         10. Immunosuppressed patients unless BOL-DP-o-04 administration is deemed safe by the&#xD;
             treating physician&#xD;
&#xD;
         11. Known Aspergillus infection&#xD;
&#xD;
         12. Panic attacks or anxiety unless a psychiatrist allowed BOL-DP-o-04 following intake&#xD;
             interview&#xD;
&#xD;
         13. Any mental/psychiatric illness in first-degree relative in a young patient &lt;&#xD;
             30-year-old.&#xD;
&#xD;
         14. Patient with congestive heart failure&#xD;
&#xD;
         15. Subjects who get the following medications: opiates, Primidone, Phenobarbitol,&#xD;
             arbamazepine, Rifampicin, Rifabutin, Troglitazone, and Hypericum perforatum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beilinson Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sciatica</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

